MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chen, Z.-S.
Right arrow Articles by Akiyama, S.-I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chen, Z.-S.
Right arrow Articles by Akiyama, S.-I.

Vol. 56, Issue 6, 1219-1228, December 1999

Effect of Multidrug Resistance-Reversing Agents on Transporting Activity of Human Canalicular Multispecific Organic Anion Transporter

Zhe-Sheng Chen, Takeshi Kawabe, Mayumi Ono, Shunji Aoki, Tomoyuki Sumizawa, Tatsuhiko Furukawa, Takeshi Uchiumi, Morimasa Wada, Michihiko Kuwano, and Shin-Ichi Akiyama

Department of Cancer Chemotherapy, Institute for Cancer Research, Faculty of Medicine, Kagoshima University, Sakuragaoka Kagoshima (Z-S.C., T.S., T.F., S.A.); Department of Medical Biochemistry, Graduate School of Medical Sciences, Kyushu University, Fukuoka (T.K., M.O., T.U., M.W., M.K.); and Graduate School of Pharmaceutical Sciences, Osaka University, Osaka, Japan (S.A.)

The canalicular multispecific organic anion transporter (cMOAT), also termed MRP2, is a recently identified ATP-binding cassette transporter. We previously established stable human cMOAT cDNA-transfected cells, LLC/cMOAT-1 from LLC-PK1 cells, and LLC/CMV cells that were transfected with an empty vector. We found that LLC/cMOAT-1 cells have increased resistance to vincristine (VCR), 7-ethyl-10-hydroxy-camptothecin, and cisplatin but not to etoposide. The multidrug resistance-reversing agents cyclosporin A (CsA) and 2-[4-(diphenylmethyl)-1-piperazinyl]-5-(trans-4,6-dimethyl-1,3,2-dioxaphosphorinan-2-yl)-2,6-dimethyl-4-(3-nitrophenyl)-3-pyridinecarboxylate P-oxide (PAK-104P) almost completely reversed the resistance to VCR, 7-ethyl-10-hydroxy-camptothecin, and cisplatin of LLC/cMOAT-1 cells; and DL-buthionine-(S,R)-sulfoximine, (3'-oxo-4-butenyl-4-methyl-threonine1, (valine2) cyclosporin (PSC833), and 3-([{3-(2-[7-chloro-2-quinolinyl]ethenyl)phenyl}-{(3-dimethylamino-3-oxopropyl)-thio}-methyl]thio)propanoic acid (MK571) partially reversed the resistance to these drugs. CsA and PAK-104P at 10 µM enhanced the accumulation of VCR in LLC/cMOAT-1 cells almost to the level in LLC/CMV cells without the agents. The efflux of VCR from LLC/cMOAT-1 cells was enhanced compared with LLC/CMV cells and inhibited by CsA and PAK-104P. Transport of leukotriene C4 (LTC4) and S-(2, 4-dinitrophenyl)glutathione also was studied with membrane vesicles prepared from these cells. LTC4 and S-(2, 4-dinitrophenyl)glutathione were actively transported into membrane vesicles prepared from LLC/cMOAT-1 cells. The Km and Vmax values for the uptake of LTC4 by the LLC/cMOAT-1 membrane vesicles were 0.26 ± 0.05 µM and 7.48 ± 0.67 pmol/min/mg protein, respectively. LTC4 transport was competitively inhibited by PAK-104P, CsA, MK571, and PSC833, with Ki values of 3.7, 4.7, 13.1, and 28.9 µM, respectively. These findings demonstrate that cMOAT confers a novel drug-resistance phenotype. CsA and PAK-104P may be useful for reversing cMOAT-mediated drug resistance in tumors.

Copyright © 1999 by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 J Biomol ScreenHome page
K. Heredi-Szabo, E. Kis, E. Molnar, A. Gyorfi, and P. Krajcsi
Characterization of 5(6)-Carboxy-2,'7'-Dichlorofluorescein Transport by MRP2 and Utilization of this Substrate as a Fluorescent Surrogate for LTC4
J Biomol Screen, April 1, 2008; 13(4): 295 - 301.
[Abstract] [PDF]

Home page
 J Clin PharmacolHome page
D. Leveque and F. Jehl
Molecular Pharmacokinetics of Catharanthus (Vinca) Alkaloids
J. Clin. Pharmacol., May 1, 2007; 47(5): 579 - 588.
[Abstract] [Full Text] [PDF]

Home page
 Physiol. Rev.Home page
R. G. Deeley, C. Westlake, and S. P. C. Cole
Transmembrane Transport of Endo- and Xenobiotics by Mammalian ATP-Binding Cassette Multidrug Resistance Proteins.
Physiol Rev, July 1, 2006; 86(3): 849 - 899.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
S. Yamaguchi, Y. L. Zhao, M. Nadai, H. Yoshizumi, X. Cen, S. Torita, K. Takagi, K. Takagi, and T. Hasegawa
Involvement of the Drug Transporters P Glycoprotein and Multidrug Resistance-Associated Protein Mrp2 in Telithromycin Transport
Antimicrob. Agents Chemother., January 1, 2006; 50(1): 80 - 87.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
R. B. Walter, J. L. Pirga, M. R. Cronk, S. Mayer, F. R. Appelbaum, and D. E. Banker
PK11195, a peripheral benzodiazepine receptor (pBR) ligand, broadly blocks drug efflux to chemosensitize leukemia and myeloma cells by a pBR-independent, direct transporter-modulating mechanism
Blood, November 15, 2005; 106(10): 3584 - 3593.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
M. Hirano, K. Maeda, H. Hayashi, H. Kusuhara, and Y. Sugiyama
Bile Salt Export Pump (BSEP/ABCB11) Can Transport a Nonbile Acid Substrate, Pravastatin
J. Pharmacol. Exp. Ther., August 1, 2005; 314(2): 876 - 882.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
K. Letschert, M. Komatsu, J. Hummel-Eisenbeiss, and D. Keppler
Vectorial Transport of the Peptide CCK-8 by Double-Transfected MDCKII Cells Stably Expressing the Organic Anion Transporter OATP1B3 (OATP8) and the Export Pump ABCC2
J. Pharmacol. Exp. Ther., May 1, 2005; 313(2): 549 - 556.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
F. Munoz-Martinez, P. Lu, F. Cortes-Selva, J. M. Perez-Victoria, I. A. Jimenez, A. G. Ravelo, F. J. Sharom, F. Gamarro, and S. Castanys
Celastraceae Sesquiterpenes as a New Class of Modulators That Bind Specifically to Human P-Glycoprotein and Reverse Cellular Multidrug Resistance
Cancer Res., October 1, 2004; 64(19): 7130 - 7138.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
E. Hopper-Borge, Z.-S. Chen, I. Shchaveleva, M. G. Belinsky, and G. D. Kruh
Analysis of the Drug Resistance Profile of Multidrug Resistance Protein 7 (ABCC10): Resistance to Docetaxel
Cancer Res., July 15, 2004; 64(14): 4927 - 4930.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
R. B. Walter, B. W. Raden, M. R. Cronk, I. D. Bernstein, F. R. Appelbaum, and D. E. Banker
The peripheral benzodiazepine receptor ligand PK11195 overcomes different resistance mechanisms to sensitize AML cells to gemtuzumab ozogamicin
Blood, June 1, 2004; 103(11): 4276 - 4284.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
M. Sugie, E. Asakura, Y. L. Zhao, S. Torita, M. Nadai, K. Baba, K. Kitaichi, K. Takagi, K. Takagi, and T. Hasegawa
Possible Involvement of the Drug Transporters P Glycoprotein and Multidrug Resistance-Associated Protein Mrp2 in Disposition of Azithromycin
Antimicrob. Agents Chemother., March 1, 2004; 48(3): 809 - 814.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Gastrointest. Liver Physiol.Home page
H. Lou, M. Ookhtens, A. Stolz, and N. Kaplowitz
Chelerythrine stimulates GSH transport by rat Mrp2 (Abcc2) expressed in canine kidney cells
Am J Physiol Gastrointest Liver Physiol, December 1, 2003; 285(6): G1335 - G1344.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
R. B. Walter, B. W. Raden, T. C. Hong, D. A. Flowers, I. D. Bernstein, and M. L. Linenberger
Multidrug resistance protein attenuates gemtuzumab ozogamicin-induced cytotoxicity in acute myeloid leukemia cells
Blood, August 15, 2003; 102(4): 1466 - 1473.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
N. Zelcer, M. T. Huisman, G. Reid, P. Wielinga, P. Breedveld, A. Kuil, P. Knipscheer, J. H. M. Schellens, A. H. Schinkel, and P. Borst
Evidence for Two Interacting Ligand Binding Sites in Human Multidrug Resistance Protein 2 (ATP Binding Cassette C2)
J. Biol. Chem., June 20, 2003; 278(26): 23538 - 23544.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. D. Chester, S. P. Joel, S. L. Cheeseman, G. D. Hall, M. S. Braun, J. Perry, T. Davis, C. J. Button, and M. T. Seymour
Phase I and Pharmacokinetic Study of Intravenous Irinotecan Plus Oral Ciclosporin in Patients With Fluorouracil-Refractory Metastatic Colon Cancer
J. Clin. Oncol., March 15, 2003; 21(6): 1125 - 1132.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
Z.-S. Chen, E. Hopper-Borge, M. G. Belinsky, I. Shchaveleva, E. Kotova, and G. D. Kruh
Characterization of the Transport Properties of Human Multidrug Resistance Protein 7 (MRP7, ABCC10)
Mol. Pharmacol., February 1, 2003; 63(2): 351 - 358.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
C. V. Hulzebos, H. Wolters, T. Plosch, W. Kramer, S. Stengelin, F. Stellaard, P. J. J. Sauer, H. J. Verkade, and F. Kuipers
Cyclosporin A and Enterohepatic Circulation of Bile Salts in Rats: Decreased Cholate Synthesis but Increased Intestinal Reabsorption
J. Pharmacol. Exp. Ther., January 1, 2003; 304(1): 356 - 363.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
X. Wang, T. Furukawa, T. Nitanda, M. Okamoto, Y. Sugimoto, S.-I. Akiyama, and M. Baba
Breast Cancer Resistance Protein (BCRP/ABCG2) Induces Cellular Resistance to HIV-1 Nucleoside Reverse Transcriptase Inhibitors
Mol. Pharmacol., January 1, 2003; 63(1): 65 - 72.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
G. C. Williams, A. Liu, G. Knipp, and P. J. Sinko
Direct Evidence that Saquinavir Is Transported by Multidrug Resistance-Associated Protein (MRP1) and Canalicular Multispecific Organic Anion Transporter (MRP2)
Antimicrob. Agents Chemother., November 1, 2002; 46(11): 3456 - 3462.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
R. Yan and E. M. Taylor
Neotrofin Is Transported Out of Brain by a Saturable Mechanism: Possible Involvement of Multidrug Resistance and Monocarboxylic Acid Transporters
Drug Metab. Dispos., May 1, 2002; 30(5): 513 - 518.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
H. Yamaguchi, I. Yano, H. Saito, and K.-i. Inui
Pharmacokinetic Role of P-Glycoprotein in Oral Bioavailability and Intestinal Secretion of Grepafloxacin in Vivo
J. Pharmacol. Exp. Ther., March 1, 2002; 300(3): 1063 - 1069.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
H. Zeng, Z.-S. Chen, M. G. Belinsky, P. A. Rea, and G. D. Kruh
Transport of Methotrexate (MTX) and Folates by Multidrug Resistance Protein (MRP) 3 and MRP1: Effect of Polyglutamylation on MTX Transport
Cancer Res., October 1, 2001; 61(19): 7225 - 7232.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
K. O. Hamilton, E. Topp, I. Makagiansar, T. Siahaan, M. Yazdanian, and K. L. Audus
Multidrug Resistance-Associated Protein-1 Functional Activity in Calu-3 Cells
J. Pharmacol. Exp. Ther., September 1, 2001; 298(3): 1199 - 1205.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
J. Liu, H. Chen, D. S. Miller, J. E. Saavedra, L. K. Keefer, D. R. Johnson, C. D. Klaassen, and M. P. Waalkes
Overexpression of Glutathione S-Transferase II and Multidrug Resistance Transport Proteins Is Associated with Acquired Tolerance to Inorganic Arsenic
Mol. Pharmacol., August 1, 2001; 60(2): 302 - 309.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
L. C. Young, B. G. Campling, S. P. C. Cole, R. G. Deeley, and J. H. Gerlach
Multidrug Resistance Proteins MRP3, MRP1, and MRP2 in Lung Cancer: Correlation of Protein Levels with Drug Response and Messenger RNA Levels
Clin. Cancer Res., June 1, 2001; 7(6): 1798 - 1804.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. Maliepaard, M. A. van Gastelen, A. Tohgo, F. H. Hausheer, R. C. A. M. van Waardenburg, L. A. de Jong, D. Pluim, J. H. Beijnen, and J. H. M. Schellens
Circumvention of Breast Cancer Resistance Protein (BCRP)-mediated Resistance to Camptothecins in Vitro Using Non-Substrate Drugs or the BCRP Inhibitor GF120918
Clin. Cancer Res., April 1, 2001; 7(4): 935 - 941.
[Abstract] [Full Text]

Home page
 Cancer Res.Home page
M. Komatsu, T. Sumizawa, M. Mutoh, Z.-S. Chen, K. Terada, T. Furukawa, X.-L. Yang, H. Gao, N. Miura, T. Sugiyama, et al.
Copper-transporting P-Type Adenosine Triphosphatase (ATP7B) Is Associated with Cisplatin Resistance
Cancer Res., March 1, 2000; 60(5): 1312 - 1316.
[Abstract] [Full Text]

Home page
 J. Biol. Chem.Home page
S. Ryu, T. Kawabe, S. Nada, and A. Yamaguchi
Identification of Basic Residues Involved in Drug Export Function of Human Multidrug Resistance-associated Protein 2
J. Biol. Chem., December 8, 2000; 275(50): 39617 - 39624.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
M. J. Harris, M. Kuwano, M. Webb, and P. G. Board
Identification of the Apical Membrane-targeting Signal of the Multidrug Resistance-associated Protein 2 (MRP2/cMOAT)
J. Biol. Chem., June 8, 2001; 276(24): 20876 - 20881.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1999 by the American Society for Pharmacology and Experimental Therapeutics